Early Predictive Value of NT-proBNP Combined With Echocardiography in Anthracyclines Induced Cardiotoxicity

Abstract

ObjectiveDetermine the predictive value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) combined with echocardiography in the diagnosis of anthracyclines-induced chronic cardiotoxicity.MethodsA total of 80 female breast cancer patients from January 2019 to October 2021 were included in our hospital. Twenty-six patients with cardiotoxicity were divided into the cardiac impairment group, and the 54 patients without cardiotoxicity were classified into the normal control group. NT-proBNP levels and cardiac echocardiography were measured before the start of the chemotherapy cycle, in cycle 3 of the chemotherapy, and after the chemotherapy cycle in all patients.ResultsAfter three cycles of chemotherapy and chemotherapy, the levels of NT-proBNP in patients of the two groups were significantly higher than those before chemotherapy (P < 0.05). The levels of NT-proBNP in the cardiac injury group after three cycles of chemotherapy and chemotherapy were higher than those in the normal control group at the same time point (P < 0.05). The LVEF of patients in the cardiac impairment group after chemotherapy was lower than that before chemotherapy, and the LVEF after chemotherapy was lower than that in the normal control group (P < 0.05). NT-proBNP had a negative correlation with LVEF (r = −0.549, P < 0.001). The AUC of NT-proBNP in combination with LVEF for predicting cardiotoxicity in our patient was 0.898(95%CI:0.829–0.966).ConclusionNT-proBNP combined with echocardiography has clinical significance in the detection of anthracyclines-induced cardiotoxicity, and it can detect early myocardial injury induced by anthracyclines, with early prediction value. It is important to protect heart function and judge prognosis.

New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

“…The studies focusing on the role of natriuretic peptides (NPs) in predicting and/or detecting CTRCD in breast cancer patients [ 86 , 87 , 90 , 91 , 92 , 96 , 97 , 98 , 99 , 100 , 101 , 103 , 105 , 106 , 109 , 113 , 114 , 117 , 118 , 119 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 ], as identified in the review, are shown in Table S1 .…”

“…Overall, the contribution of troponins, NT-proBNP or BNP, and LVEF and associated parameters in detecting and monitoring CTRCD is undoubtable, but additional studies are required in order to define their exact roles to predict CTRCD. The studies focusing on the role of LVEF, strain changes, and other imaging biomarkers in predicting and/or detecting CTRCD in breast cancer patients [ 84 , 91 , 94 , 95 , 99 , 108 , 109 , 113 , 118 , 119 , 130 , 131 , 132 , 133 , 137 , 139 , 141 , 142 , 146 , 147 , 148 , 149 , 150 , 151 , 153 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 …”

“…Overall, the contribution of troponins, NT-proBNP or BNP, and LVEF and associated parameters in detecting and monitoring CTRCD is undoubtable, but additional studies are required in order to define their exact roles to predict CTRCD. The studies focusing on the role of LVEF, strain changes, and other imaging biomarkers in predicting and/or detecting CTRCD in breast cancer patients [84,91,94,95,99,108,109,113,118,119,[130][131][132][133]137,139,141,142,[146][147][148][149][150][151]153,, as identified in the review, are shown in Table S1.…”